Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Protriptyline is a tricyclic antidepressant (TCA) used primarily for the treatment of depression and, in some cases, anxiety. It is classified as a secondary amine TCA and works by inhibiting the reuptake of norepinephrine and serotonin in the central nervous system, thereby increasing their levels in the brain[1][2][3][4][6]. This action enhances serotonergic neurotransmission, which is believed to underlie its antidepressant effects. Protriptyline also blocks histamine H1 receptor, alpha-1 adrenergic receptor, and muscarinic receptor—contributing to its side effect profile including anticholinergic effects such as dry mouth and urinary retention[4]. Compared to other TCAs, it tends to be less sedating[1]. Protriptyline has also been used off-label for conditions such as attention-deficit/hyperactivity disorder (ADHD), panic disorder, obsessive-compulsive disorder (OCD), enuresis (bedwetting), bulimia nervosa, cocaine dependency, bipolar depression phase, and as support in smoking cessation programs[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on protriptyline.